CERO Therapeutics Holdings, Inc. announced on September 9, 2025, that it received a Notice of Allowance from the U.S. Patent and Trademark Office for Application 19/019,111. The patent, once issued, will provide the company with comprehensive composition of matter protection for CER-1236 and protection for its use to treat cancer, extending through 2041.
This newly allowed U.S. application is expected to provide the most comprehensive protection specific to CER-1236 to date. Additionally, the company obtained a patent in Japan, which provides protection for the broader CER platform technology.
These additions bring the total to 18 granted patents and 2 allowed applications covering CER-1236 and its platform technology internationally. CEO Chris Ehrlich stated that the company's intellectual property portfolio is stronger than ever, and combined with recent FDA Fast Track and Orphan Drug Designations, CERO is in a strong regulatory position regarding exclusivity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.